CD74-ROS Fusion Protein Detection in NSCLC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective identification and targeting of novel gene translocations and mutations in human cancers, particularly in non-small cell lung carcinoma (NSCLC), which limits the development of specific therapeutics and diagnostics.
Innovation Solution
Identification of a novel gene translocation (5q32, 6q22) resulting in CD74-ROS fusion proteins, along with the development of methods and reagents for detecting these proteins, enabling the detection of mutant ROS kinase activity and inhibiting cancer progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional cancer detection and treatment methods are used, then general cancer care is provided, but specific identification and targeting of gene translocations and mutations in NSCLC is limited
Solution Approach 1:
The patent uses CD74 as an intermediary marker to detect ROS kinase gene translocations. By detecting the presence of CD74-ROS fusion protein or mRNA, the system indirectly identifies the translocation event without directly observing the chromosomal rearrangement, thereby improving detection precision while managing complexity through a surrogate marker approach
Solution Approach 2:
The patent replaces complex cytogenetic analysis methods (such as karyotyping or FISH) with molecular biology techniques like RT-PCR or immunohistochemistry. This substitution allows for more precise detection of specific gene translocations while standardizing the detection process and reducing operational complexity
2Reliability
If targeted therapy is developed for specific mutant proteins, then treatment efficacy is improved, but the ability to identify suitable patients is limited without specific detection methods
Solution Approach 1:
The patent employs CD74 as a detectable marker that serves as an intermediary for identifying patients with ROS kinase translocations. By detecting CD74 expression patterns or CD74-ROS fusion transcripts, clinicians can identify suitable candidates for ROS kinase inhibitor therapy, bridging the gap between genetic mutation and clinically actionable diagnostic information
Solution Approach 2:
The patent establishes a feedback loop where detection of CD74-ROS fusion proteins or transcripts provides information that guides therapeutic decisions. This feedback mechanism ensures that targeted therapy is administered only to patients whose tumors express the specific translocation, thereby improving treatment reliability while making patient selection feasible through standardized detection assays
Data Source
AI summary
In accordance with the invention, a novel gene translocation, (5q32, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in a fusion proteins combining part of CD74 with Proto-oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The CD74-ROS fusion protein is anticipated to drive the proliferation and survival of a subgroup of NSCLC tumors. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of the new fusion protein enables new methods for determining the presence of these mutant ROS kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.